TriSalus Life Sciences, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(unaudited, in thousands except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $9,167 | $6,457 |
| Cost of goods sold | 1,495 | 971 |
| Gross profit | 7,672 | 5,486 |
| Operating expenses: | ||
| Research and development | 3,296 | 5,844 |
| Sales and marketing | 6,734 | 6,687 |
| General and administrative | 4,971 | 4,627 |
| Loss from operations | (7,329) | (11,672) |
| Other income (expense): | ||
| Interest income | 74 | 92 |
| Interest expense | (1,209) | (3) |
| Change in fair value of SEPA, warrant, and revenue base redemption liabilities | (835) | 2,521 |
| Change in fair value of contingent earnout liability | (820) | (3,988) |
| Other expense, net | (251) | (153) |
| Loss before income taxes | (10,370) | (13,203) |
| Income tax expense | (5) | (3) |
| Net loss available to common stockholders | $(10,375) | $(13,206) |
| Undeclared dividends on Series A preferred stock | $(712) | $(801) |
| Net loss attributable to common stockholders | $(11,087) | $(14,007) |
| Net loss per common share, basic and diluted | $(0.39) | $(0.60) |
| Weighted average common shares outstanding, basic and diluted | 28,527,453 | 23,323,045 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.